▶ 調査レポート

世界の神経筋遮断薬(NMBA)市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global Neuromuscular Blocking Agent (NMBA) Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の神経筋遮断薬(NMBA)市場 2021:企業別、地域別、種類・用途別 / Global Neuromuscular Blocking Agent (NMBA) Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 / GIR-2104Z09919資料のイメージです。• レポートコード:GIR-2104Z09919
• 出版社/出版日:GlobalInfoResearch / 2021年4月
※2025年版があります。お問い合わせください。

• レポート形態:英文、PDF、101ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医療・医薬品
• 販売価格(消費税別)
  Single User¥487,200 (USD3,480)▷ お問い合わせ
  Multi User¥730,800 (USD5,220)▷ お問い合わせ
  Corporate User¥974,400 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、神経筋遮断薬(NMBA)のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。神経筋遮断薬(NMBA)の種類別市場規模(脱分極、非脱分極)、用途別市場規模(病院、診療所、薬局、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・神経筋遮断薬(NMBA)の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):AbbVie、GlaxoSmithKline、Pfizer、Hengrui Pharmaceutical、Abbott Laboratories、Fresenius Kabi、Sandoz、Somerset Therapeutics、Guike Pharmaceutical、Shanghai Pharmaceuticals、Themis Medicare、Nanjing King-Friend
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:脱分極、非脱分極
・用途別分析2016年-2026年:病院、診療所、薬局、その他
・神経筋遮断薬(NMBA)の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・神経筋遮断薬(NMBA)のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・神経筋遮断薬(NMBA)のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・神経筋遮断薬(NMBA)の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・神経筋遮断薬(NMBA)の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Neuromuscular Blocking Agent (NMBA) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Neuromuscular Blocking Agent (NMBA) size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Neuromuscular Blocking Agent (NMBA) market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Neuromuscular Blocking Agent (NMBA) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Depolarizing
Non-depolarizing

Market segment by Application can be divided into
Hospital
Clinic
Pharmacy
Others

The key market players for global Neuromuscular Blocking Agent (NMBA) market are listed below:
AbbVie
GlaxoSmithKline
Pfizer
Hengrui Pharmaceutical
Abbott Laboratories
Fresenius Kabi
Sandoz
Somerset Therapeutics
Guike Pharmaceutical
Shanghai Pharmaceuticals
Themis Medicare
Nanjing King-Friend

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

レポート目次

1 Market Overview
1.1 Neuromuscular Blocking Agent (NMBA) Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuromuscular Blocking Agent (NMBA) Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Depolarizing
1.2.3 Non-depolarizing
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuromuscular Blocking Agent (NMBA) Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Others
1.4 Global Neuromuscular Blocking Agent (NMBA) Market Size & Forecast
1.4.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Value (2016-2026))
1.4.2 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume (2016-2026)
1.4.3 Global Neuromuscular Blocking Agent (NMBA) Price by Type (2016-2026) & (USD/MT)
1.5 Global Neuromuscular Blocking Agent (NMBA) Production Capacity Analysis
1.5.1 Global Neuromuscular Blocking Agent (NMBA) Total Production Capacity (2016-2026)
1.5.2 Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuromuscular Blocking Agent (NMBA) Market Drivers
1.6.2 Neuromuscular Blocking Agent (NMBA) Market Restraints
1.6.3 Neuromuscular Blocking Agent (NMBA) Trends Analysis
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Neuromuscular Blocking Agent (NMBA) Product and Services
2.1.4 AbbVie Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product and Services
2.2.4 GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Neuromuscular Blocking Agent (NMBA) Product and Services
2.3.4 Pfizer Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Hengrui Pharmaceutical
2.4.1 Hengrui Pharmaceutical Details
2.4.2 Hengrui Pharmaceutical Major Business
2.4.3 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services
2.4.4 Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Abbott Laboratories
2.5.1 Abbott Laboratories Details
2.5.2 Abbott Laboratories Major Business
2.5.3 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product and Services
2.5.4 Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Fresenius Kabi
2.6.1 Fresenius Kabi Details
2.6.2 Fresenius Kabi Major Business
2.6.3 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product and Services
2.6.4 Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Sandoz
2.7.1 Sandoz Details
2.7.2 Sandoz Major Business
2.7.3 Sandoz Neuromuscular Blocking Agent (NMBA) Product and Services
2.7.4 Sandoz Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Somerset Therapeutics
2.8.1 Somerset Therapeutics Details
2.8.2 Somerset Therapeutics Major Business
2.8.3 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product and Services
2.8.4 Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.9 Guike Pharmaceutical
2.9.1 Guike Pharmaceutical Details
2.9.2 Guike Pharmaceutical Major Business
2.9.3 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services
2.9.4 Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.10 Shanghai Pharmaceuticals
2.10.1 Shanghai Pharmaceuticals Details
2.10.2 Shanghai Pharmaceuticals Major Business
2.10.3 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product and Services
2.10.4 Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.11 Themis Medicare
2.11.1 Themis Medicare Details
2.11.2 Themis Medicare Major Business
2.11.3 Themis Medicare Neuromuscular Blocking Agent (NMBA) Product and Services
2.11.4 Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.12 Nanjing King-Friend
2.12.1 Nanjing King-Friend Details
2.12.2 Nanjing King-Friend Major Business
2.12.3 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product and Services
2.12.4 Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Neuromuscular Blocking Agent (NMBA) Sales by Manufacturer
3.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Neuromuscular Blocking Agent (NMBA)
3.4 Market Concentration Rate
3.4.1 Top 3 Neuromuscular Blocking Agent (NMBA) Manufacturer Market Share
3.4.2 Top 6 Neuromuscular Blocking Agent (NMBA) Manufacturer Market Share
3.5 Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Neuromuscular Blocking Agent (NMBA) Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neuromuscular Blocking Agent (NMBA) Market Size by Region
4.1.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Region (2016-2026)
4.1.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2016-2026)
4.2 North America Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
4.3 Europe Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
4.4 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
4.5 South America Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
4.6 Middle East and Africa Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Type (2016-2026)
5.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2016-2026)
5.3 Global Neuromuscular Blocking Agent (NMBA) Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Neuromuscular Blocking Agent (NMBA) Sales in Volume by Application (2016-2026)
6.2 Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2016-2026)
6.3 Global Neuromuscular Blocking Agent (NMBA) Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
7.2 North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
7.3 North America Neuromuscular Blocking Agent (NMBA) Market Size by Country
7.3.1 North America Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2016-2026)
7.3.2 North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
8.2 Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
8.3 Europe Neuromuscular Blocking Agent (NMBA) Market Size by Country
8.3.1 Europe Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2016-2026)
8.3.2 Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
9.2 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
9.3 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Market Size by Region
9.3.1 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
10.2 South America Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
10.3 South America Neuromuscular Blocking Agent (NMBA) Market Size by Country
10.3.1 South America Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2016-2026)
10.3.2 South America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2026)
11.2 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2026)
11.3 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Market Size by Country
11.3.1 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Neuromuscular Blocking Agent (NMBA) Typical Distributors
12.3 Neuromuscular Blocking Agent (NMBA) Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type, (USD Million), 2021-2026
Table 2. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application, (USD Million), 2021-2026
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Neuromuscular Blocking Agent (NMBA) Product and Services
Table 6. AbbVie Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline Major Business
Table 9. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Product and Services
Table 10. GlaxoSmithKline Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Pfizer Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Major Business
Table 13. Pfizer Neuromuscular Blocking Agent (NMBA) Product and Services
Table 14. Pfizer Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Hengrui Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 16. Hengrui Pharmaceutical Major Business
Table 17. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services
Table 18. Hengrui Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 20. Abbott Laboratories Major Business
Table 21. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Product and Services
Table 22. Abbott Laboratories Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 24. Fresenius Kabi Major Business
Table 25. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Product and Services
Table 26. Fresenius Kabi Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Sandoz Basic Information, Manufacturing Base and Competitors
Table 28. Sandoz Major Business
Table 29. Sandoz Neuromuscular Blocking Agent (NMBA) Product and Services
Table 30. Sandoz Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Somerset Therapeutics Basic Information, Manufacturing Base and Competitors
Table 32. Somerset Therapeutics Major Business
Table 33. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Product and Services
Table 34. Somerset Therapeutics Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Guike Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Guike Pharmaceutical Major Business
Table 37. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Product and Services
Table 38. Guike Pharmaceutical Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Shanghai Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 40. Shanghai Pharmaceuticals Major Business
Table 41. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Product and Services
Table 42. Shanghai Pharmaceuticals Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Themis Medicare Basic Information, Manufacturing Base and Competitors
Table 44. Themis Medicare Major Business
Table 45. Themis Medicare Neuromuscular Blocking Agent (NMBA) Product and Services
Table 46. Themis Medicare Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Nanjing King-Friend Basic Information, Manufacturing Base and Competitors
Table 48. Nanjing King-Friend Major Business
Table 49. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Product and Services
Table 50. Nanjing King-Friend Neuromuscular Blocking Agent (NMBA) Sales (MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Global Neuromuscular Blocking Agent (NMBA) Sales by Manufacturer (2019-2021e) & (MT)
Table 52. Global Neuromuscular Blocking Agent (NMBA) Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 53. Market Position of Manufacturers in Neuromuscular Blocking Agent (NMBA), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 54. Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Company, (MT): 2020 VS 2021
Table 55. Head Office and Neuromuscular Blocking Agent (NMBA) Production Site of Key Manufacturer
Table 56. Global Neuromuscular Blocking Agent (NMBA) Sales by Region (2016-2021e) & (MT)
Table 57. Global Neuromuscular Blocking Agent (NMBA) Sales by Region (2021-2026) & (MT)
Table 58. Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2016-2021e) & (USD Million)
Table 59. Global Neuromuscular Blocking Agent (NMBA) Revenue by Region (2021-2026) & (USD Million)
Table 60. Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 61. Global Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 62. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2016-2021e) & (USD Million)
Table 63. Global Neuromuscular Blocking Agent (NMBA) Revenue by Type (2021-2026) & (USD Million)
Table 64. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2016-2021e) & (USD/MT)
Table 65. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2021-2026) & (USD/MT)
Table 66. Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 67. Global Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 68. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2016-2021e) & (USD Million)
Table 69. Global Neuromuscular Blocking Agent (NMBA) Revenue by Application (2021-2026) & (USD Million)
Table 70. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2016-2021e) & (USD/MT)
Table 71. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2021-2026) & (USD/MT)
Table 72. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2016-2021e) & (MT)
Table 73. North America Neuromuscular Blocking Agent (NMBA) Sales by Country (2021-2026) & (MT)
Table 74. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2021e) & (USD Million)
Table 75. North America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2021-2026) & (USD Million)
Table 76. North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 77. North America Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 78. North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 79. North America Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 80. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2016-2021e) & (MT)
Table 81. Europe Neuromuscular Blocking Agent (NMBA) Sales by Country (2021-2026) & (MT)
Table 82. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2021e) & (USD Million)
Table 83. Europe Neuromuscular Blocking Agent (NMBA) Revenue by Country (2021-2026) & (USD Million)
Table 84. Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 85. Europe Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 86. Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 87. Europe Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 88. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2016-2021e) & (MT)
Table 89. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Region (2021-2026) & (MT)
Table 90. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2016-2021e) & (USD Million)
Table 91. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue by Region (2021-2026) & (USD Million)
Table 92. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 93. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 94. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 95. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 96. South America Neuromuscular Blocking Agent (NMBA) Sales by Country (2016-2021e) & (MT)
Table 97. South America Neuromuscular Blocking Agent (NMBA) Sales by Country (2021-2026) & (MT)
Table 98. South America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2021e) & (USD Million)
Table 99. South America Neuromuscular Blocking Agent (NMBA) Revenue by Country (2021-2026) & (USD Million)
Table 100. South America Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 101. South America Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 102. South America Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 103. South America Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 104. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2016-2021e) & (MT)
Table 105. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Country (2021-2026) & (MT)
Table 106. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2016-2021e) & (USD Million)
Table 107. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue by Country (2021-2026) & (USD Million)
Table 108. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2016-2021e) & (MT)
Table 109. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Type (2021-2026) & (MT)
Table 110. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2016-2021e) & (MT)
Table 111. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales by Application (2021-2026) & (MT)
Table 112. Direct Channel Pros & Cons
Table 113. Indirect Channel Pros & Cons
Table 114. Neuromuscular Blocking Agent (NMBA) Typical Distributors
Table 115. Neuromuscular Blocking Agent (NMBA) Typical Customers
List of Figures
Figure 1. Neuromuscular Blocking Agent (NMBA) Picture
Figure 2. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type in 2020
Figure 3. Depolarizing
Figure 4. Non-depolarizing
Figure 5. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application in 2020
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Pharmacy
Figure 9. Others
Figure 10. Global Neuromuscular Blocking Agent (NMBA) Market Size, (USD Million) & (MT): 2020 VS 2021 VS 2026
Figure 11. Global Neuromuscular Blocking Agent (NMBA) Market Size and Forecast (2016-2026) & (USD Million)
Figure 12. United States Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Canada Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Mexico Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Germany Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. France Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. United Kingdom Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Russia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Italy Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. China Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Japan Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Korea Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. India Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Southeast Asia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Australia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Brazil Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Egypt Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Saudi Arabia Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. South Africa Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Turkey Neuromuscular Blocking Agent (NMBA) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Global Neuromuscular Blocking Agent (NMBA) Sales (2016-2026) & (MT)
Figure 32. Global Neuromuscular Blocking Agent (NMBA) Production Capacity (2016-2026) & (MT)
Figure 33. Global Neuromuscular Blocking Agent (NMBA) Production Capacity by Geographic Region: 2020 VS 2021
Figure 34. Neuromuscular Blocking Agent (NMBA) Market Drivers
Figure 35. Neuromuscular Blocking Agent (NMBA) Market Restraints
Figure 36. Neuromuscular Blocking Agent (NMBA) Market Trends
Figure 37. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Manufacturer in 2020
Figure 38. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Manufacturer in 2020
Figure 39. Neuromuscular Blocking Agent (NMBA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 40. Top 3 Neuromuscular Blocking Agent (NMBA) Manufacturer (Revenue) Market Share in 2020
Figure 41. Top 6 Neuromuscular Blocking Agent (NMBA) Manufacturer (Revenue) Market Share in 2020
Figure 42. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2016-2026)
Figure 43. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2016-2026)
Figure 44. North America Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 45. Europe Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 46. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 47. South America Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 48. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue (2016-2026) & (USD Million)
Figure 49. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 50. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Type (2016-2026)
Figure 51. Global Neuromuscular Blocking Agent (NMBA) Price by Type (2016-2026) & (USD/MT)
Figure 52. Global Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 53. Global Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Application (2016-2026)
Figure 54. Global Neuromuscular Blocking Agent (NMBA) Price by Application (2016-2026) & (USD/MT)
Figure 55. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2016-2026)
Figure 56. North America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2016-2026)
Figure 57. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 58. North America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 59. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2016-2026)
Figure 60. Europe Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2016-2026)
Figure 61. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 62. Europe Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 63. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Region (2016-2026)
Figure 66. Asia-Pacific Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 67. South America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2016-2026)
Figure 68. South America Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2016-2026)
Figure 69. South America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 70. South America Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 71. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Revenue Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Type (2016-2026)
Figure 74. Middle East & Africa Neuromuscular Blocking Agent (NMBA) Sales Market Share by Application (2016-2026)
Figure 75. Sales Channel: Direct Channel vs Indirect Channel
Figure 76. Methodology
Figure 77. Research Process and Data Source